Home > Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Search results for: Tisagenlecleucel for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukaemia in People Aged up to 25 Years: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Sorry No Items for your query, please try with :
Tisagenlecleucel Treatment Relapsed Refractory Bcell Acute Lymphoblastic Leukaemia People Aged 25Years Evidence Review Group Perspective NICE Single Technology Appraisal